Piper Sandler Maintains Overweight on Abbott Laboratories, Lowers Price Target to $115

Benzinga Newsdesk www.benzinga.com Negative 80.6%

Neg 80.6% Neu 0% Pos 0%

Piper Sandler analyst Adam Maeder maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $135 to $115.